Health Care & Life Sciences » Biotechnology | GeneOneLifeScience Inc.

GeneOneLifeScience Inc. | Income Statement

Fiscal year is January-December. All values KRW Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
20,657
24,625
28,365
31,371
27,171
34,293
Cost of Goods Sold (COGS) incl. D&A
17,902
21,993
21,698
24,137
22,212
24,598
Gross Income
2,755
2,632
6,667
7,234
4,959
9,694
SG&A Expense
9,065
9,122
10,294
21,229
29,821
20,953
EBIT
6,310
6,490
3,627
13,994
24,862
11,259
Unusual Expense
1,301
12
-
-
147
3,405
Non Operating Income/Expense
137
95
3,664
501
2,949
3,985
Interest Expense
820
144
44
1,239
1,843
1,391
Pretax Income
8,327
6,362
291
14,399
23,283
11,735
Income Tax
36
130
1,122
1,200
447
162
Consolidated Net Income
8,363
6,492
1,414
15,599
23,730
11,898
Net Income
8,363
6,492
1,414
15,599
23,730
11,898
Net Income After Extraordinaries
8,363
6,492
1,414
15,599
23,730
11,898
Net Income Available to Common
8,363
6,492
1,414
15,599
23,730
11,898
EPS (Basic)
132.47
90.89
81.71
897.91
1,329.00
567
Basic Shares Outstanding
63
71
17
17
18
21
EPS (Diluted)
132.23
91.29
81.83
898.19
1,329.35
566.56
Diluted Shares Outstanding
63
71
17
17
18
21
EBITDA
4,416
4,855
2,478
12,862
23,757
9,965
Non-Operating Interest Income
241
190
298
332
325
335

About GeneOneLifeScience

View Profile
Address
Unit 1903, Keungil Tower
Seoul SL 06142
Korea, Republic Of
Employees -
Website http://www.genels.com
Updated 07/08/2019
GeneOne Life Science, Inc. engages in the research, development, and manufacture of deoxyribonucleic acid (DNA) vaccines for the prevention and treatment of diseases. Its products include VGX-3400, VGX-3500, and fluprime. Its service include process cost analysis, sterility testing, research batch production, strain selection, cell bank characterization, and others.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.